Australia Tga Medical Device Registration Consultant
An Australia TGA medical device registration consultant should resolve the regulatory route before anyone commissions extra tests or submits an ARTG application. The useful deliverable is a reasoned decision on product scope, Australian classification, acceptable evidence, sponsor readiness and the gaps that can block market entry—not an assurance of approval.
The Therapeutic Goods Administration (TGA) administers the Australian Register of Therapeutic Goods (ARTG). Most medical devices require inclusion before supply, subject to applicable exclusions and exemptions. This advisory framework also covers in-vitro diagnostics (IVDs) and software only where their specific rules have first been considered.
Start with the intended purpose and legal scope
Freeze one consistent intended-purpose statement across instructions for use, labels, promotional claims, software functionality, patient population and clinical setting. The manufacturer determines the Australian device classification by applying the relevant rules; an EU or US class is not an Australian classification.
First decide whether the product meets the Australian medical-device or IVD definition, or whether a lawful exclusion or exemption applies. Then identify the “kind of medical device” proposed for inclusion; do not assume every catalogue SKU needs a separate ARTG entry or that unrelated variants can share one.
Route-choice matrix: which facts change the answer?
Use this decision table as a screening tool, not as a classification ruling. Confirm the particular Schedule 2 or 2A rules and the supporting evidence for the actual device.
| Decision trigger | What the consultant should decide next |
|---|---|
| Therapeutic claims, software decision support, or an IVD testing purpose | Assess medical-device/IVD status and any exclusions before assigning a class; review actual claims, function, user and specimen or patient context. |
| Invasiveness, duration, anatomical site, active function, or multiple functions | Apply all relevant Australian classification rules; test whether the highest applicable rule changes the evidence route. |
| Class I non-sterile/non-measuring or Class 1 IVD, versus other classes | Check the applicable self-declaration and Manufacturer Evidence identifier exception; do not confuse an identifier exception with exemption from conformity or ARTG obligations. |
| Existing EU/UK/US approval or conformity documents | Map authority, certificate scope, manufacturer, product identification, validity and relevant TGA evidence pathway; overseas approval alone does not grant Australian market access. |
| No Australian sponsor, or another sponsor already has the device included | Confirm an eligible Australian-based sponsor and an evidence-access agreement. ARTG entries are sponsor-specific; another sponsor’s entry does not automatically cover your supply. |
Reuse overseas evidence without assuming automatic acceptance
Test overseas regulatory evidence in two separate layers: (1) manufacturer/QMS evidence suitable for the device class and TGA pathway, and (2) product-level information needed for preliminary assessment or a possible application audit. The TGA guidance on comparable overseas regulators specifies the applicable combinations; acceptance is conditional, not mutual recognition of every foreign certificate.
Build a reconciliation sheet for model identifiers, legal manufacturer, intended purpose, risk class, certificate scope and dates, Australian Declaration of Conformity, clinical/performance evidence, risk management, labelling and instructions for use. A CE mark or ISO 13485 certificate is not by itself proof that every Australian Essential Principle is met. Document mismatches as open issues rather than silently rewriting the claims.
Prioritise gaps before buying tests or filing
Rate each difference by its effect on the legal route. A “stop” item requires resolution before the planned application; a “bridge” item needs justified supplementary evidence; a “maintain” item requires a post-market owner.
| Gap found | Decision and consequence |
|---|---|
| Intended purpose differs across EU documents and Australian marketing | STOP: agree controlled claims and reassess device status, classification, certificate scope and clinical evaluation before submission. |
| Foreign certificate does not cover the proposed device or is no longer valid | STOP/ROUTE CHANGE: determine if acceptable replacement conformity evidence or an Australian assessment route is needed. |
| Essential Principles mapping, clinical/performance support or Australian labelling is incomplete | BRIDGE: specify the evidence or corrections needed; decide only then whether targeted testing, analysis or clinical work is justified. |
| UDI, sponsor evidence access, vigilance or change-control ownership is unclear | MAINTAIN/STOP AS APPLICABLE: assign owners and assess current UDI phase and transitional arrangements before supply. |
A staged consulting decision, not a filing checklist
Request a written advisory output with explicit assumptions, evidence owners and unresolved decisions. A practical order is:
- Collect intended purpose, IFU/labels/advertising, device descriptions, variant list, manufacturer identity, prior approvals and planned Australian distribution model.
- Make a documented device-status and classification assessment, including IVD/software/special-case rules and any plausible exemption; mark disputed facts.
- Choose the conformity assessment and evidence route; verify the current TGA comparable-overseas-regulator tables and manufacturer-evidence exceptions.
- Complete an Essential Principles and clinical/performance evidence gap map; commission only the additional work supported by a defined gap.
- Agree sponsor responsibilities, UDI applicability, budget drivers, audit-readiness and a change-control trigger list; authorise filing only once the route is defensible.
Sponsor accountability and changes after inclusion
The Australian sponsor is the regulatory contact and must be able to obtain manufacturer information when the TGA requests it. An overseas manufacturer needs an Australian sponsor, and the manufacturer remains responsible for classification and conformity documentation. A consultant may advise either party but does not become the sponsor merely by giving advice.
Before approving a launch, check the current UDI phase: obligations began on 1 July 2026 for specified Class IIb and III devices, with later phases and transitional provisions depending on device circumstances. Plan for recordkeeping, post-market incident reporting, corrective action, and reassessment if claims, design, certification, sponsor or device group change. Timelines, fees and audit selection are case-specific and should not be promised in advance.
Where advice ends and execution begins
This page owns strategic classification and gap decisions. The neighbouring pages cover the mechanics of submitting an application, acting as a local sponsor and wider Australian market-access routing:
Official TGA references
Frequently asked questions
Can an EU MDR certificate replace Australian TGA registration?
No. It may support an eligible evidence route, depending on its scope, issuing body, device and current TGA guidance. The Australian sponsor must still assess the applicable ARTG inclusion pathway; a foreign certificate does not itself create an ARTG entry.
Does a low-risk Class I device need no Australian paperwork?
Do not assume so. Some Class I devices follow self-declaration routes and do not require a Manufacturer Evidence identifier, but classification, applicable Essential Principles, documentation and ARTG obligations must still be checked.
Can two Australian distributors use one sponsor’s ARTG entry?
Not automatically. An ARTG entry is tied to its sponsor, manufacturer and kind of device. Each party’s actual import or supply role must be assessed and an appropriate sponsor arrangement established.
Should we order a new clinical study before consulting a specialist?
Usually first perform the intended-purpose, class and evidence gap analysis. Existing clinical, analytical, literature and post-market evidence may be relevant; whether new investigation is needed is device-specific and cannot be answered from the product name.
What if software gains a new diagnostic claim after inclusion?
Treat it as a change trigger: reassess intended purpose, applicable classification rules, evidence, labelling and whether the ARTG entry or conformity route remains suitable. Also review UDI and post-market consequences where applicable.